Search

BioMerieux

Suletud

SektorTervishoid

113.4

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

113.2

Max

113.5

Põhinäitajad

By Trading Economics

Sissetulek

-56M

161M

Müük

1.3B

2B

P/E

Sektori keskmine

35.079

37.461

Dividenditootlus

0.82

Kasumimarginaal

7.877

Töötajad

14,147

EBITDA

314M

476M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+12.53% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.82%

2.33%

Turustatistika

By TradingEconomics

Turukapital

-319M

13B

Eelmine avamishind

113.4

Eelmine sulgemishind

113.4

Uudiste sentiment

By Acuity

50%

50%

147 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

BioMerieux Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. apr 2025, 08:49 UTC

Suurimad hinnamuutused turgudel

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

BioMerieux Prognoos

Hinnasiht

By TipRanks

12.53% tõus

12 kuu keskmine prognoos

Keskmine 127.5 EUR  12.53%

Kõrge 140 EUR

Madal 120 EUR

Põhineb 5 Wall Streeti analüütiku instrumendi BioMerieux 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

2

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

113.1 / 118.6Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

147 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
help-icon Live chat